The sale gave Yuri Sudhakar a date for the company history. On March 4, 2019, BioTelemetry completed its acquisition of Geneva. A business he had helped build now belonged to a larger organization. The founder’s next assignment was already there: he continued as Geneva’s president and a senior vice president at its buyer. Selling a company, in this case, came with more company to run.
There is something useful about beginning his story at that point. An acquisition supplies the satisfying punctuation that a business biography craves. Here is the enterprise, here is the buyer, here is the announcement. But a full stop would misrepresent what followed. Within months, Sudhakar was advising other entrepreneurs. Less than two years later, he was launching Nudj Health.
Those moves make a particular career visible. Sudhakar has sold software, helped build a company, remained inside it after a transaction and returned to founding. The interesting question is what travels between those jobs. A contact list can travel. So can an understanding of customers. Judgment has to make the journey too, carrying its less photogenic luggage: decisions revised, disagreements endured and promises that eventually have to become somebody’s daily work.
A degree in the world, a career in software
Before the executive titles, there were social sciences. Sudhakar studied political science, economics and history at the University of California, Santa Barbara, followed by a master’s at American University in international development and economics. The subjects range across institutions, incentives and the ways people organize their lives. His eventual career would take him into the commercial machinery of organizations.
His early professional record includes Siebel Systems, Oracle, Symantec, Anakam and Okta. These are distinct businesses, but enterprise software provides a common setting: products are bought by organizations with existing systems, established habits and several people entitled to say no. A good demonstration may begin a sale. It rarely completes all the work required to make a product part of an institution.
At Anakam, an internet security company, Sudhakar held a senior sales role before its acquisition by Equifax. That experience placed him on the commercial side of a growing business and a corporate transaction before Geneva. His route to founding ran through the practical business of persuading customers to adopt technology.
The distinction matters when looking at his later companies. A founder with a sales background has spent time at the point where ambition meets an actual buyer. The buyer has a budget, colleagues and a reason to be cautious. In Sudhakar’s career, that encounter precedes the CEO title. It offers one way to read his continuing interest in how products fit inside organizations.
The buyer still had work to do
Sudhakar became Geneva’s co-founder and CEO in 2013. By 2018, the company was formalizing its internal training through a business unit called Geneva University. The initiative focused on continuous improvement in both specialist and administrative processes. It is an unglamorous detail, which makes it useful. Growing a business involves teaching people to do the work consistently, including tasks that will never fit into an announcement headline.
The acquisition terms announced in January 2019 included $45 million in upfront cash and additional performance-based payments of at least $20 million. The transaction closed in March. Keeping the two parts of the consideration separate gives a clearer picture of the deal: a payment at closing, followed by money tied to performance. The distinction is more informative than a single large number.
Announced January 28. Completed March 4.
BioTelemetry’s closing announcement described its next priorities for Geneva as customer acquisition and revenue growth. It expected to invest in the business and did not anticipate an earnings contribution in the first year after the acquisition. The buyer’s account leaves the operating challenge plainly visible. Ownership had changed; the need to build the business continued.
Sudhakar stayed in leadership. That places another experience between the startup and his next venture: running a business after it has entered a larger company. The transaction can be celebrated on one day. Making the combined organization work occupies a rather longer diary.
A new desk on the other side of the pitch
In July 2019, BAHA Enterprises announced that Sudhakar was joining its advisor network. The role connected his operating experience with entrepreneurs and investors. Its scope included business guidance and work with the investor network on due diligence. For someone accustomed to making the case for his own company, it offered another place to examine the case being made by others.
His listed advisory subjects were concrete: go-to-market strategy, product strategy, raising capital, partnerships, scaling and mergers and acquisitions. They describe the jobs around the invention, the work needed to turn a promising idea into an organization that customers can buy from. A pitch can move through all those subjects in twelve slides. A company takes longer.
His own announcement offered “experience, scars, and insights.” The inclusion of scars gives the sentence its interest. Advice based on operating experience ought to contain some recognition of its cost. By 2020, Sudhakar was also named among new investor-advisors supporting Diasyst. Building and advising were becoming overlapping chapters.
Ten million dollars, and a familiar question
Sudhakar left BioTelemetry in late 2020. He teamed up with investment partner Donald Cohn, whose background was in real estate, and launched Nudj in February 2021. The new business put him back in the founder’s chair. Cohn joined its board. The calendar provides a compact sequence: an acquisition, continued leadership, advisory work and another launch.
In April 2022, Nudj announced a $10 million Series A led by Nebraska Medicine, Teal Ventures, HIP and the Cohn Family Trust. The stated use of the money included expanding technology and commercial teams. Funding gave the business resources to pursue its next stage; it also made execution the next subject on the agenda.
The investors’ explanations focused partly on the people. Nebraska Medicine highlighted the leadership team’s previous experience of scaling a virtual business and working within customers’ existing operations. Teal Ventures pointed to an experienced team and a focused strategy. These were arguments about the organization’s ability to deliver, alongside the idea it was selling.
Some working relationships carried over. Earl Bray had been Geneva’s finance chief before becoming Nudj’s CFO. Jeff Marchese, Nudj’s technology chief, was another longtime collaborator. A second company can arrive with a new name while some of the conversations have years behind them. Familiarity provides context; every new decision still requires its own discussion.
- 2013Co-founds Geneva
- 2019Geneva sale closes; joins BAHA’s advisor network
- 2021Launches Nudj
- 2022Nudj announces $10m Series A
By 2026, the company was adding relationships around that core team. In January, it announced David B. Nash’s appointment to its advisory board. In June, Nudj and Loma Linda University Health announced a collaboration. These are different kinds of company milestones from a funding round: one brings an advisor into the discussion, the other puts two organizations into a working relationship.
For a founder, each expands the circle of people involved in delivery. An investor asks how a business can grow. A partner needs agreement about how the work will happen. An advisor brings another perspective to decisions. Taken together, the announcements show the continuing organizational work behind the title of CEO.
A different kind of currency
In 2022, Sudhakar connected empathy with company resilience. He described becoming more empathetic as an intentional practice, including when making consequential decisions. That emphasis puts a human question beside the financial milestones: how does a company retain the capacity to work together when decisions become difficult?
“Empathy is the currency that allows you to build company resilience.”
Yuri Sudhakar, 2022
The currency metaphor is practical. It treats empathy as something with a function inside a company. A chief executive depends on other people’s understanding, attention and willingness to report what is happening. A budget can assign resources. It cannot, by itself, create the quality of conversation that determines where those resources should go.
His emphasis also complicates the familiar account of a founder as the person with the answer. Building requires answers from colleagues with different responsibilities. The commercial team sees one set of pressures. Technology sees another. The CEO must make a decision that can survive contact with both.
The argument that stayed in the story
In September 2026, Sudhakar described a heated argument with Marchese at a WeWork over their platform’s technical direction. Other members of the shared workspace witnessed the exchange. He recalled it as an uncomfortable episode that remained part of their shared understanding of the work.
The account appeared in his essay “The Hard Way,” which used filmmaking as an analogy for operating experience. He described two startups built together and a collaboration stretching across fourteen years. The anecdote lets disagreement remain visible inside that continuity. A long working relationship can contain both.
That is a fitting place to leave his story for now. The Geneva sale supplies a date; the next company supplies another beginning. Between them are customers, colleagues, capital and decisions. Sudhakar’s career keeps returning to the task of organizing those things into a business. The win gets an announcement. The work gets another meeting.